WuXi Biologics Receives EMA GMP Certificates for Trogarzo

WuXi Biologics has received EMA GMP certificates for the production of Trogarzo at its cGMP Drug Substance and Drug Product manufacturing facilities in Wuxi city and its cGMP cell banking facilities in Shanghai. Trogarzo, an HIV treatment, is developed by TaiMed Biologics and marketed in the U.S. and EU by Theratechnologies.
 
“This marks yet another great milestone that WuXi Biologics has achieved and lays a solid foundation for us to significantly expand our manufacturing capacity and capabilities,” said Dr. Chris Chen, chief executive officer of WuXi Biologics. “With the recognition from both the U.S. FDA and EMA, WuXi Biologics will continue to enable our global partners to accelerate and transform biologics development from concept to commercialization.”